EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC 4.0

Primary Resistance to RET Inhibition in a RET Fusion-Positive Pancreatic Neuroendocrine Carcinoma

Blake J McKinley iD, Tucker W Coston, Jason S Starr iD

The Oncologist · 2025

DOI: 10.1093/oncolo/oyae034 ↗

Kurz gefasst

Fallbericht in der Zeitschrift The Oncologist, 2025. Verfasst von Blake J McKinley und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Mayo Clinic, Jacksonville, FL, USA. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-ret, Carcinoma, Neuroendocrine, Pancreatic Neoplasms, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We present a 54-year-old White male with a diagnosis of stage IV pancreatic neuroendocrine carcinoma. Next-generation sequencing of the tumor/blood identified a complex tumor genome, which included a rearranged during transfection (RET) gene fusion. The patient initially received cytotoxic chemotherapy with a significant radiographic response. After 4 cycles of chemotherapy, the patient was transitioned to a clinical trial using selpercatinib, a RET inhibitor, as maintenance therapy. Unfortunately, our patient developed progression of disease at the first treatment monitoring scan. Our patient suffered primary resistance to RET-targeted therapy. Proposed mechanisms of resistance include intrinsic resistance of the nuclear receptor co-activator 4-RET fusion to RET inhibition, the RET fusion representing a passenger alteration to another tumorigenic driver pathway and/or decreased efficacy of RET inhibition after platinum-based chemotherapy. Our patient’s clinical course highlights the fact that “actionable” genomic alterations do not always equate to patient benefit.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins c-retCarcinoma, NeuroendocrinePancreatic NeoplasmsDrug Resistance, NeoplasmOncogene Proteins, FusionHumansMaleMiddle AgedPyrazolesPyridines

Stichwörter der Autor:innen

RET fusionpancreatic neuroendocrine cancerprimary resistanceselpercatinib

Substanzen

Proto-Oncogene Proteins c-retRET protein, humanOncogene Proteins, FusionselpercatinibPyrazolesPyridines

Autor:innen und Institutionen

  • Department of Internal Medicine, Mayo Clinic, Jacksonville, FL, USA.
  • Division of Medical Oncology, Duke, Raleigh, NC, USA.
  • Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, FL, USA.

ORCID-Profile: Blake J McKinley, Jason S Starr

Zitieren

APA

McKinley, B. J., Coston, T. W., & Starr, J. S. (2025). Primary Resistance to RET Inhibition in a RET Fusion-Positive Pancreatic Neuroendocrine Carcinoma. The Oncologist. https://doi.org/10.1093/oncolo/oyae034

Vancouver

McKinley BJ, Coston TW, Starr JS. Primary Resistance to RET Inhibition in a RET Fusion-Positive Pancreatic Neuroendocrine Carcinoma. The Oncologist. 2025. doi:10.1093/oncolo/oyae034

BibTeX
@article{McKinley2025,
  author = {McKinley, Blake J and Coston, Tucker W and Starr, Jason S},
  title = {Primary Resistance to RET Inhibition in a RET Fusion-Positive Pancreatic Neuroendocrine Carcinoma},
  journal = {The Oncologist},
  year = {2025},
  doi = {10.1093/oncolo/oyae034}
}
Kostenlos starten →